Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Lower adrenal hormone levels may cause hair loss in postmenopausal women, certain patterns help diagnose nail cancer, and a gene variant linked to higher skin cancer risk in kidney transplant patients suggests monitoring folate levels.

This study suggests a potential causal link between frontal fibrosing alopecia and vitiligo, as observed in two cases where the conditions co-occurred on preexisting vitiligo of the forehead.

This article is a commentary on another piece about the clinical efficacy of oral finasteride and reports no new results.

This study found that female pattern hair loss may be influenced by genetic factors and hormonal changes, particularly in young adults, and identified specific dermoscopic features associated with the condition.

This article reviews the characteristics of female androgenetic alopecia, highlighting its hormonal and genetic factors, and reports no new experimental findings; the authors note various life stages when hair loss may occur.

This review examines hair and skin disorders in post-menopausal women and notes a lack of evidence supporting specific treatments for this population.

This review discusses hormonal changes during menopause, emphasizing the relative androgen excess and the role of insulin resistance, and reports no new clinical findings.

This case report discusses a postmenopausal woman whose hyperandrogenism and metabolic symptoms improved significantly after the surgical removal of an ovarian Leydig cell tumor, confirmed post-operatively.

This study found that menopausal status and hormone therapy significantly affect the histology and gene expression of the introitus, with post-menopausal women showing notable tissue remodeling associated with vaginal atrophy.

This article describes various acute and chronic vulvar disorders post-menopause and summarizes identification and treatment strategies, but reports no new clinical findings.

This article highlights that hormonal changes during menopause can significantly affect hair health, leading to decreased hair density, altered texture, and increased hair disorders, which may subsequently impact emotional well-being in women.

This review discusses the effects of oestrogen on skin ageing and highlights the need for large-scale clinical trials to evaluate postmenopausal oestrogen use, reporting no new findings.

This review focuses on the clinical presentation and management challenges of menopausal acne and reports no new experimental findings.

This case report describes a 23-year-old woman with an adult granulosa cell tumor of the ovary, whose symptoms and hormone levels improved significantly after surgical removal of the tumor.

This study reports two cases of frontal fibrosing alopecia in postmenopausal women, suggesting it as a variant of lichen planopilaris due to similar histological findings yet distinct clinical presentation.

This review examines the characteristics of frontal fibrosing alopecia in postmenopausal women, highlighting the importance of biopsy for early diagnosis and potential treatment to prevent disease progression.

This study found that postmenopausal women with lichen planopilaris showed a high prevalence of androgen excess, while women with frontal fibrosing alopecia were often associated with androgen deficiency.

This study highlights a rare case of ovarian hyperthecosis in a 58-year-old postmenopausal woman, presenting with polycythemia and severe hyperandrogenism symptoms, with resolution of symptoms following laparoscopic bilateral oophorectomy.

In this study, Brazilian postmenopausal women reported that menopause significantly deteriorates the quality of their skin, nails, and hair, negatively affecting self-esteem and quality of life, with a need for better understanding of hormone replacement therapy's dermatological effects.

This study reported that postmenopausal patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival over therapy-related side effects when considering cancer treatment decisions.

This case study reported that prolonged use of the cancer drug Erlotinib in a postmenopausal woman was associated with trichomegaly and hypertrichosis, highlighting the importance of considering medication history in such cases.

This case report highlights Leydig cell hyperplasia as a rare cause of increased testosterone and postmenopausal hirsutism, resolved after bilateral salpingo-oophorectomy in a 64-year-old woman.

This study found that postmenopausal women in Argentina with frontal fibrosing alopecia had a higher average age of diagnosis than previously reported, with similar clinical features to international cases.

This study describes a postmenopausal woman's diagnosis with ovarian hyperthecosis, confirmed by a GnRHa test normalizing testosterone, highlighting hormone therapy as a therapeutic option when surgery is not feasible.

This study reviewed 18 postmenopausal women with frontal fibrosing alopecia, noting frontotemporal hairline recession and eyebrow loss, often treated with steroids, triamcinolone, and other medications.

This study found that postmenopausal women experience two distinct patterns of hair changes, with diffuse scalp hair loss linked to body hair loss and age, and frontal hair loss associated with increased facial hair and a younger age.

This study found that a topical combination of 0.25% finasteride and 3% minoxidil may increase hair diameter more effectively than 3% minoxidil alone in postmenopausal women with female pattern hair loss.

This case report details a postmenopausal woman with increased libido, hirsutism, and spontaneous orgasms, noting elevated testosterone levels and enlarged ovaries.

This case report describes a post-menopausal woman with severe hirsutism whose high testosterone levels decreased after gonadotropin suppression, indicating residual hormone-producing tissue responsive to gonadotropins.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.